Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354293 | 0.88 | TSHR (0.35) | RAPGEF4AHRCYP3A4TSHRMAPT | |
| SCHEMBL3028712 | 0.83 | ALDH1A1 (0.45) | ALDH1A1AHRCYP3A4TSHRRECQL | |
| SCHEMBL6358686 | 0.82 | TSHR (0.38) | RAPGEF4ALDH1A1TSHRMAPTL3MBTL1 | |
| SCHEMBL14932492 | 0.79 | RAPGEF4 (0.41) | RAPGEF4P2RX7ALDH1A1AHRCYP3A4 | |
| SCHEMBL10051058 | 0.79 | RAPGEF4 (0.41) | RAPGEF4P2RX7ALDH1A1AHRCYP3A4 | |
| SCHEMBL25247894 | 0.78 | SCN4A (0.30) | RAPGEF4SCN4A | |
| SCHEMBL21803257 | 0.78 | SCN4A (0.30) | SCN4A | |
| SCHEMBL6151899 | 0.77 | RAPGEF4 (0.39) | RAPGEF4P2RX7ALDH1A1AHRCYP3A4 | |
| SCHEMBL110348 | 0.77 | KRAS (0.40) | RAPGEF4P2RX7ALDH1A1AHRKRAS | |
| SCHEMBL27129026 | 0.77 | RAPGEF4 (0.39) | RAPGEF4P2RX7ALDH1A1AHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154007-A1 | New compounds | AMIN KOSRAT (SE) | 2005-07-14 | — | — | US | disclosed |
| US-6790960-B2 | Compounds | ASTRAZENECA AB (SE) | 2004-09-14 | — | — | US | disclosed |
| EP-1411056-A2 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for their preparation | AstraZeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030220364-A1 | New compounds | AMIN KOSRAT (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6579884-B1 | Compounds | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220364-A1 | New compounds | SLC10A2, GIPR, FABP2 | RAPGEF4 1067/4885P2RX7 394/4885ALDH1A1 1399/4885 |
| US-20050154007-A1 | New compounds | SLC10A2, GIPR, FABP6 | RAPGEF4 963/4885P2RX7 413/4885ALDH1A1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.